Universal Beteiligungs und Servicegesellschaft mbH Raises Position in Regeneron Pharmaceuticals, Inc. $REGN

Universal Beteiligungs und Servicegesellschaft mbH raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 108,871 shares of the biopharmaceutical company’s stock after acquiring an additional 827 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Regeneron Pharmaceuticals were worth $84,179,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $34,000. FNY Investment Advisers LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $38,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 3,774 shares of company stock worth $2,942,738. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Oppenheimer restated an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $811.96.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Major label expansions for Dupixent — U.S. approval as the first biologic for children 2–11 with uncontrolled chronic spontaneous urticaria (CSU) and a recent European Commission approval broaden pediatric indications, supporting additional addressable market and revenue tailwinds. Dupixent US Approval Dupixent EU Approval
• Positive Sentiment: Cemdisiran phase‑3 success in generalized myasthenia gravis (gMG) — strong NIMBLE trial results (published in The Lancet) and a submitted U.S. regulatory application point to a high‑value pipeline asset and potential first‑in-class siRNA approval. Cemdisiran Phase 3
• Positive Sentiment: Analyst commentary expects EPS growth and a likely earnings beat, which could provide upside if results and guidance exceed consensus. Earnings Preview
• Neutral Sentiment: Regeneron is hosting investor events and presenting at major conferences (BofA, Goldman Sachs) in May–June — useful for management commentary but may only cause short‑term moves. Investor Presentations
• Neutral Sentiment: Company discussion/transcript on the C5 complement program (cemdisiran + pozelimab) provides technical and clinical detail for investors assessing pipeline optionality. C5 Program Transcript
• Negative Sentiment: Valuation and momentum concerns — analysis notes that recent approvals and collaborations (including a Telix radiopharmaceutical tie‑up) are in place but shares have underperformed year‑to‑date, suggesting some investors view these wins as already priced in or insufficient to change longer‑term growth trajectory. That skepticism is likely weighing on the stock. Valuation Analysis

Regeneron Pharmaceuticals Trading Down 0.1%

Shares of REGN opened at $746.58 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a market capitalization of $78.93 billion, a P/E ratio of 17.96, a P/E/G ratio of 1.66 and a beta of 0.40. The firm has a 50-day moving average price of $764.22 and a 200 day moving average price of $729.68. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm earned $12.07 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.2 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.